PIN1 and cancer: EGCG can inhibit peptidyl-prolyl isomerase NIMA-interacting 1 (PIN1) activity, an enzyme that binds to and catalyses the conversion of proline-directed serine/threonine phosphorylation, could disrupt the balance of oncogenes and tumour suppressors promoting oncogenesis19–21, which point out the therapeutic potential of PIN1 inhibitors in cancer therapy.